FS-1 Drug for Treatment of Multiple Drug-resistant Tuberculosis

Summary

Drug-resistant tuberculosis is becoming a major problem for the whole humanity, and development of new Anti-TB drugs is of great importance. Since Kazakhstan is a country with the high burden of tuberculosis, the Government of the Republic of Kazakhstan has founded initiative on the development of new Anti-TB drug to treat drug-resistant forms of this infectious disease. JSC "Scientific Center for Anti-infectious Drugs" has developed original drug FS-1 for the treatment of multidrug resistant tuberculosis (MDR-TB).

Conditions

• Tuberculosis, MDR

Interventions

DRUG

FS-1

FS-1 is a liquid solution for internal intake and has antimicrobial and antibacterial activities.

DRUG

Placebo

Placebo without any active pharmaceutical ingredients

Sponsors & Collaborators

• Phthisiopulmonology Center of Almaty, Kazakhstan

  collaborator UNKNOWN

• National Scientific Center of Phthisiopulmonology, Kazakhstan

  collaborator UNKNOWN

• Karaganda Medical University

  collaborator OTHER

• West Kazakhstan Marat Ospanov Medical University, Aktobe, Kazakhstan

  collaborator UNKNOWN

• Semey State Medical University

  collaborator OTHER

• National Center of Phthisiatry, Bishkek, Kyrgyzstan

  collaborator OTHER

• Invivo laboratory, Kazakhstan

  collaborator UNKNOWN

• Scientific Center for Anti-infectious Drugs, Kazakhstan

  lead INDUSTRY

Principal Investigators

• Amirkan A Azembayev, Cond.Phar.Sc. · JSC "Scientific Center for Anti-infectious Drugs"

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

QUADRUPLE

Model

PARALLEL

Eligibility

Min Age

18 Years

Max Age

65 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2013-12-31

Primary Completion

2020-08-31

Completion

2020-10-31

Countries

• Kazakhstan
• Kyrgyzstan

Study Locations